Ibex granted FDA breakthrough device designation

Ibex Medical Analytics

9 June 2021 - Ibex's Galen AI powered platform is recognised by the FDA as breakthrough technology with the potential to more effectively diagnose cancer.

Ibex Medical Analytics today announced the granting of breakthrough device designation by the U.S. FDA, which will help fast track the clinical review and regulatory approval of its platform.

Ibex's Galen platform uses Strong AI algorithms to help pathologists improve the quality of cancer diagnosis, implement real time quality control, reduce diagnosis time and boost productivity. It has already demonstrated outstanding outcomes in clinical studies and is deployed in labs worldwide where it is used as part of everyday clinical practice.

Read Ibex Medical Analytics press release

Michael Wonder

Posted by:

Michael Wonder